Abstract
e21005 Background: Tumor pathophysiological conditions depending on tumor cell metabolism and tumor microenvironment offer an opportunity to better characterize tumors by providing metabolic signature. Metabolomics is the combination of analytical techniques such as Nuclear Magnetic Resonance (NMR) spectroscopy with statistical data analysis methods aimed to evaluate the metabolic status of biofluids. This technology may be relevant for breast cancer prognosis. Therefore, the first objective of this study was to provide evidence that metabolomics from patients' (pts) blood sample is able to distinguish between metastatic and localized breast cancer. Methods: Serum samples from 2 cohorts of pts were analyzed using 1H NMR spectroscopy on a Bruker Avance III spectrometer operating at 800 MHz and equipped with a triple resonances automated TXI probe. Fasting blood sample were drawn from 30 pts with localized breast cancer (before surgery), and from 25 pts with metastatic breast cancer (before the first chemotherapy injection). For each sample, a 1D NMR spectrum was acquired, showing a large number of resonances corresponding to protons belonging to different classes of metabolites. A spectral database was generated, and bioinformatic tools were used to analyze the results using supervised multivariate analysis (Partial Least Square Regression). Results: The use of very high-field NMR allows the acquisition of resolved spectra with a reliable assignment of resonances based on multidimensional homo- and heteronuclear experiments. We identify metabolic signature of metastatic breast cancer, which is statistically different from the metabolic signature of localized breast cancer. Target analysis is on going to have further quantitative analysis of a class of metabolites that are related to the metastatic condition. Conclusions: Metabolomics may become a novel biomarker for cancer prognosis. Prospective studies to validate metabolomics as a prognostic/predictive tool are planed. No significant financial relationships to disclose.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
